Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by DnB Asset Management AS

DnB Asset Management AS raised its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 1.4% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 201,281 shares of the medical research company's stock after purchasing an additional 2,810 shares during the period. DnB Asset Management AS owned 0.05% of Thermo Fisher Scientific worth $104,712,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Geode Capital Management LLC increased its stake in Thermo Fisher Scientific by 1.7% in the third quarter. Geode Capital Management LLC now owns 7,659,943 shares of the medical research company's stock worth $4,719,477,000 after purchasing an additional 127,564 shares during the period. Coldstream Capital Management Inc. grew its stake in Thermo Fisher Scientific by 11.4% in the 3rd quarter. Coldstream Capital Management Inc. now owns 9,705 shares of the medical research company's stock worth $5,972,000 after acquiring an additional 995 shares in the last quarter. Greenwood Gearhart Inc. raised its stake in shares of Thermo Fisher Scientific by 9.8% during the third quarter. Greenwood Gearhart Inc. now owns 20,579 shares of the medical research company's stock valued at $12,730,000 after acquiring an additional 1,837 shares in the last quarter. Nordea Investment Management AB grew its stake in Thermo Fisher Scientific by 23.6% in the fourth quarter. Nordea Investment Management AB now owns 55,452 shares of the medical research company's stock worth $28,868,000 after purchasing an additional 10,606 shares in the last quarter. Finally, S.E.E.D. Planning Group LLC raised its position in Thermo Fisher Scientific by 6.2% during the 4th quarter. S.E.E.D. Planning Group LLC now owns 10,626 shares of the medical research company's stock valued at $5,528,000 after purchasing an additional 618 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Remove Ads

Insiders Place Their Bets

In related news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $175,677.00. Following the completion of the sale, the executive vice president now owns 16,363 shares of the company's stock, valued at approximately $9,582,009.17. This trade represents a 1.80 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Stephen Williamson sold 9,825 shares of the firm's stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $5,753,421.75. Following the completion of the sale, the chief financial officer now directly owns 27,296 shares of the company's stock, valued at $15,984,264.64. This trade represents a 26.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 23,900 shares of company stock valued at $13,106,062 in the last 90 days. 0.34% of the stock is owned by insiders.

Thermo Fisher Scientific Stock Performance

TMO stock traded down $7.51 during trading on Tuesday, hitting $490.09. 707,954 shares of the company traded hands, compared to its average volume of 1,616,197. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. Thermo Fisher Scientific Inc. has a 1 year low of $484.27 and a 1 year high of $627.88. The stock's 50-day simple moving average is $540.37 and its 200 day simple moving average is $551.02. The company has a market cap of $184.89 billion, a PE ratio of 29.66, a P/E/G ratio of 2.99 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. On average, equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Friday, March 14th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, March 14th. This represents a $1.72 dividend on an annualized basis and a yield of 0.35%. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 10.41%.

Wall Street Analyst Weigh In

TMO has been the subject of several recent research reports. Raymond James restated an "outperform" rating and issued a $667.00 price objective (up from $650.00) on shares of Thermo Fisher Scientific in a report on Monday, February 3rd. Bank of America reduced their price objective on shares of Thermo Fisher Scientific from $675.00 to $660.00 and set a "buy" rating for the company in a research note on Friday, December 13th. Morgan Stanley lifted their target price on Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an "overweight" rating in a research note on Friday, January 31st. Citigroup lowered their price target on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. Finally, UBS Group boosted their price objective on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a "buy" rating in a research note on Friday, January 31st. Four analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $653.23.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.